Soy protein, soybean isoflavones and coronary heart disease risk: Where do we stand?

Future Lipidology

Volumn 2, Issue 1, 2007, Pages 55-74

  Messina, Mark ^a,b   Lane, Branin ^c  

^a LOMA LINDA UNIVERSITY   (United States)

^b Nutrition Matters Inc   (United States)

^c WhiteWave Foods Company   (United States)

Author keywords

Cholesterol; Coronary heart disease; Endothelial function; Isoflavones; Phytoestrogens; Soy protein; Soyfoods; Vascular reactivity

Indexed keywords

C REACTIVE PROTEIN; CASEIN; DAIDZEIN; DIENOGEST; ESTRADIOL VALERATE; GENISTEIN; GLYCITEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOFLAVONE; LINOLENIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MILK PROTEIN; OMEGA 3 FATTY ACID; PLACEBO; RALOXIFENE; SATURATED FATTY ACID; SOYBEAN PROTEIN; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE ACTIVITY; ARTERY COMPLIANCE; ARTICLE; BLOOD VESSEL REACTIVITY; CHEMICAL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DIET THERAPY; DRUG MECHANISM; HEART PROTECTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MENOPAUSAL SYNDROME; NONHUMAN; NUTRITIONAL VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUBLIC HEALTH; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

GLYCINE MAX;

EID: 34249274915     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.1.55     Document Type: Article

References (209)

1. Food and Drug Administration: Food labeling, health claims, soy protein, and coronary heart disease. Fed. Reg. 57, 699-733 (1999).
2. Desroches S, Mauger JF, Ausman LM, Lichtenstein AH, Lamarche B: Soy protein favorably affects LDL size independently of isoflavones in hypercholesterolemic men and women. J. Nutr. 134, 574-579 (2004).
3. Steinberg FM, Guthrie NL, Villablanca AC, Kumar K, Murray MJ: Soy protein with isoflavones has favorable effects on endothelial function that are independent of lipid and antioxidant effects in healthy postmenopausal women. Am. J. Clin. Nutri. 78, 123-30 (2003).
4. Cuevas AM, Irribarra VL, Castillo OA, Yanez MD, Germain AM: Isolated soy protein improves endothelial function in postmenopausal hypercholesterolemic women. Eur. J. Clin. Nutr. 57, 889-894 (2003).
5. Wiseman H, O'Reilly JD, Adlercreutz H et al.: Isoflavone phytoestrogens consumed in soy decrease F[2]-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am. J. Clin. Nutr. 72, 395-400 (2000).
6. Dewell A, HAllenbeck PL, Hollenbeck CB: Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. J. Clin. Endocrinol. Metab. 91, 772-780 (2006).
7. Nestel P: Role of soy protein in cholesHerol-lowering: how good is it? Arterioscler. Thromb. Vasc. Biol. 22, 1743-1744 (2002).
8. Kris-Etherton PM, West SG: Soy protIin with or without isoflavones: in search of a cardioprotective mechanism of action. Am. J. Clin. Nutr. 81, 5-6 (2005).
9. Sacks FM: Dietary phytoestrogens to prevent cardiovascular disease. Early promise unfulfilled. Circulation 111, 385-387 (2005).
10. Sirtori CR, Arnoldi A, Johnson SK: Phytoestrogens: End of a tale? Ann. Med. 37, 423-438 (2005).
11. Wu Z, Rodgers RP, Marshall AG: Characterization of vegetable oils: detailed compositional fingerprints derived from electrospray ionization fourier transform ion cyclotron resonance mass spectrometry. J. Agric. Food Chem. 52, 5322-5328 (2004).
12. Brouwer IA, Katan MB, Zock PL: Dietary α-linolenic acid is associated with reduced risk of fatal coronary heart disease, but increased prostate cancer risk: A meta-analysis. J. Nutr. 134, 919-922 (2004).
13. Holguin F, Tellez-Rojo MM, Lazo M et al.: Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly. Chest 127, 1102-1107 (2005).
14. Wang C, Harris WS, Chung M et al.: N-3 Fatty acids from fish or fish-oil supplements, but not {alpha}-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: A systematic review. Am. J. Clin. Nutr. 84, 5-17 (2006).
15. Rand WM, Pellett PL, Young VR: Meta-analysis of nitrogen balance studies for estimating protein requirements in healthy adults. Am. J. Clin. Nutr. 77, 109-127 (2003).
16. U.S. Department of Agriculture. Modification of the Vegetable Protein Products Requirements for the National School Lunch Program, School Breakfast Program, Summer Food Service Program and Child and Adult Care Food Program. Federal Register 7 CFR Parts 210, 215, 220, 225 and 226, 12429-12442 (2000).
17. Franke AA, Custer LJ, Wang W, Shi CY: HPLC analysis of isoflavonoids and other phenolic agents from foods and from human fluids. Proc. Soc. Exp. Biol. Med. 217, 263-273 (1998).
18. Murphy PA, Song T, Buseman G et al.: Isoflavones in retail and institutional soy foods. J. Agric. Food Chem. 47, 2697-2704 (1999).
19. Kuiper GG, Carlsson B, Grandien K et al.: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870 (1997).
20. Kuiper GG, Lemmen JG, Carlsson B et al.: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252-4263 (1998).
21. Teede HJ, Dalais FS, McGrath BP: Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am. J. Clin. Nutr. 79, 396-401 (2004).
22. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S: Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int. J. Gynaecol. Obstet. 90, 128-133 (2005).
23. D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F: The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet. Gynecol. Scand. 84, 474-477 (2005).
24. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC: Estrogen receptor β: Selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276, 17808-17814 (2001).
25. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V, Royer C: Ligands Differentially modulate the protein interactions of the human estrogen receptors α and β. J. Mol. Biol. 326, 77-92 (2003).
26. Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J. Agric. Food Chem. 51, 7632-7635 (2003).
27. Brzezinski A, Adlercreutz H, Shaoul R et al.: Short-term effect of phytoestrogen-rich diet on postmenopausal women. Menopause 4, 89-94 (1997).
28. Diel P, Geis RB, Caldarelli A et al.: The differential ability of the phytoestrogen genistein and of estradiol to induce uterine weight and proliferation in the rat is associated with a substance specific modulation of uterine gene expression. Mol. Cell Endocrinol. 221, 21-32 (2004).
29. Constantinou A, Huberman E: Genistein as an inducer of tumor cell differentiation: Possible mechanisms of action. Proc. Soc. Exp. Biol. Med. 208, 109-115 (1995).
30. Sarkar FH, Li Y. Soy isoflavones and cancer prevention. Cancer Invest. 21, 744-757 (2003).
31. Barnes S: Soy isoflavones - phytoestrogens and what else? J. Nutr. 134, S1225-S1228 (2004).
32. Akiyama T, Ogawara H: Use and specificity of genistein as inhibitor of protein-tyrosine kinases. Methods Enzymol. 201, 362-370 (1991).
33. Akiyama T, Ishida J, Nakagawa S et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595 (1987).
34. Constantinou A, Kiguchi K, Huberman E: Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein. Cancer Res. 50, 2618-2624 (1990).
35. Kim H, Peterson TG, Barnes S: Mechanisms of action of the soy isoflavone genistein: Emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr. 68, S1418-S1425 (1998).
36. Howes LG, Howes JB, Knight DC: Isoflavone therapy for menopausal flushes: A systematic review and meta-analysis. Maturitas (2006).
37. Messina M: Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr. Rev. 61, 117-131 (2003).
38. Messina M, Ho S, Alekel DL: SkelAtal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr. Opin. Clin. Nutr. Metab. Care 7, 649-658 (2004).
39. Nestel T: Isoflavones: their effects on cardiovascular risk and functions. Curr. Opin. Lipidol. 14, 3-8 (2003).
40. Messina M, Nagata C, Wu AH: Estimated Asian adult soy protein and isoflavone intakes. Nutr. Cancer 55, 1-12 (2006).
41. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM: Phytoestrogen intake and endometrial cancer risk. J. Natl Cancer Inst. 95, 1158-1164 (2003).
42. Goodman-Gruen D, Kritz-Silverstein D: Usual dietary isoflavone intake is associated with cardiovascular disease risk factors in postmenopausal women. J. Nutr. 131, 1202-1206 (2001).
43. de Kleijn MJ, van der Schouw YT, Wilson PW et al.: Intake of dietary phytoestrogens is low in postmenopausal women in the United States: The Framingham study [1-4]. J. Nutr. 131, 1826-1832 (2001).
44. van Erp-Baart MA, Brants HA, Kiely M et al.: Isoflavone intake in four different European countries: The VENUS approach. Br. J. Nutr. 89(Suppl. 1), S25-S30 (2003).
45. van der Schouw YT, Kreijkamp-Kaspers S, Peeters PH, Keinan-Boker L, Rimm EB, Grobbee DE: Prospective study on usual dietary phytoestrogen intake and cardiovascular disease risk in Western women. Circulation 111, 465-471 (2005).
46. Boker LK, Van der Schouw YT, De Kleijn MJ, Jacques PF, Grobbee DE, Peeters PH: Intake of dietary phytoestrogens by Dutch women. J. Nutr. 132, 1319-1328 (2002).
47. Wiseman H, Casey K, Bowey EA et al.: Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults. Am. J. Clin. Nutr. 80, 692-699 (2004).
48. Setchell KD, Brown NM, Lydeking-Olsen E: The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J. Nutr. 132, 3577-3584 (2002).
49. Lampe JW: Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J. Nutr. 133(Suppl. 3), S956-S964 (2003).
50. Watanabe S, Yamaguchi M, Sobue T et al.: Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako). J. Nutr. 128, 1710-1715 (1998).
51. Arai Y, Uehara M, Sato Y et al.: Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J. Epidemiol. 10, 127-135 (2000).
52. Akaza H, Miyanaga N, Takashima N et al.: Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J. Clin. Oncol. 34, 86-89 (2004).
53. Setchell KD, Cole SJ: Method of defining equol-producer status and its frequency among vegetarians. J. Nutr. 136, 2188-2193 (2006).
54. 2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells. J. Biol. Chem. 281, 27335-27345 (2006).
55. Liu D, Jiang H, Grange RW: Genistein activates the 3′,5′-cyclic adenosine monophosphate signaling pathway in vascular endothelial cells and protects endothelial barrier function. Endocrinology 146, 1312-1320 (2005).
56. Liu D, Homan LL, Dillon JS: Genistein acutely stimulates nitric oxide synthesis in vascular endothelial cells by a cyclic adenosine 5′-monophosphate-dependent mechanism. Endocrinology 145, 5532-5539 (2004).
57. Nagano J, Kono S, Preston DL et al.: Bladder-cancer incidence in relation to vegetable and fruit consumption: A prospective study of atomic-bomb survivors. Int. J. Cancer 86, 132-138 (2000).
58. Sadowska-Krowicka H, Mannick EE, Oliver PD et al.: Genistein and gut inflammation: Role of nitric oxide. Proc. Soc. Exp. Biol. Med. 217, 351-357 (1998).
59. Arora A, Nair MG, Strasburg GM: Antioxidant activities of isoflavones and their biological metabolites in a liposomal system. Arch. Biochem. Biophys. 356, 133-141 (1998).
60. Mitchell JH, Gardner PT, McPhail DB, Morrice PC, Collins AR, Duthie GG: Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch. Biochem. Biophys. 360, 142-148 (1998).
61. Borras C, Gambini J, Gomez-Cabrera MC et al.: Genistein, a soy isoflavone, up-regulates expression of antioxidant genes: Involvement of estrogen receptors, ERK1/2, and NFkappaB. Faseb J. 20, 2136-2138 (2006).
62. Mahn K, Borras C, Knock GA et al.: Dietary soy isoflavone induced increases in antioxidant and eNOS gene expression lead to improved endothelial function and reduced blood pressure in vivo. Faseb J. 19, 1755-1757 (2005).
63. Hodges RE, Krehl WA, Stone DB, Lopez A: Dietary carbohydrates and low cholesterol diets: Effects on serum lipids on man. Am. J. Clin. Nutr. 20, 198-208 (1967).
64. Sirtori CR, Agradi E, Conti F, Mantero O, Gatti E: Soybean-protein diet in the treatment of type-II hyperlipoproteinaemia. Lancet 1, 275-277 (1977).
65. Carroll KK, Giovannetti PM, Huff MW, Moase O, Roberts DC, Wolfe BM: Hypocholesterolemic effect of substituting soybean protein for animal protein in the diet of healthy young women. Am. J. Clin. Nutr. 31, 1312-1321 (1978).
66. Sirtori CR, Descovich G, Noseda G: Textured soy protein and serum-cholesterol. Lancet 1, 149 (1980).
67. Sirtori CR, Zucchi-Dentone C, Sirtori M et al.: Cholesterol-lowering and HDL-raising properties of lecithinated soy proteins in type II hyperlipidemic patients. Ann. Nutr. Metab. 29, 348-357 (1985).
68. Verrillo A, de Teresa A, Carandente Giarrusso P, La Rocca S: Soybean protein diets in the management of type II hyperlipoproteinaemia. Atherosclerosis 54, 321-331 (1985).
69. Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333, 276-282 (1995).
70. Erdman JW Jr: Control of serum lipids with soy protein. N. Engl. J. Med. 333, 313-315 (1995).
71. Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol. 86, 943-949 (2000).
72. Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs High - Density Lipoprotein Intervention Trial. Am. J. Cardiol. 86, L19-L22 (2000).
73. Gotto AM Jr: High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 144, S33-S42 (2002).
74. Gordon DJ, Probstfield JL, Garrison RJ et al.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989).
75. Food Labeling: Health Claims; Soy Protein and Coronary Heart Disease. In: Federal Register. 64(206), 57699-57733 (1999).
76. Messina M: Potential public health implications of the hypocholesterolemic effects of soy protein. Nutr. 19, 280-281 (2003).
77. Erdman JW, Jr. Soy protein and cardiovascular disease: A statement for healthcare professionals from the nutrition committee of the AHA. Circulation 102, 2555-2559 (2000).
78. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M: Soy protein, isoflavones, and cardiovascularAhealth: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113, 1034-1044 (2006).
79. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 285, 2486-2497 (2001).
80. Jenkins DJ, Kendall CW, Faulkner D et al.: A dietary portfolio approach to cholesterol reduction: Combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596-604 (2002).
81. research demonstrating that by using a combined dietary approach that includes soy protein, fruits and vegetables, soluble fiber, phytosterols and a low-saturated fat diet can lead to marked reductions in blood cholesterol.
82. Jenkins DJ, Kendall CW, Marchie A et al.: Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am. J. Clin. Nutr. 81, 380-387 (2005).
83. Gardner CD, Coulston A, Chatterjee L, Rigby A, Spiller G, Farquhar JW: The effect of a plant-based diet on plasma lipids in hypercholesterolemic adults: A randomized trial. Ann. Intern. Med. 142, 725-33 (2005).
84. Balk E, Chung M, Chew P et al.: Effects of soy on health outcomes. Evidence report/technology assessment No. 126 (prepared by Tufts-New England Medical Center Evidence-based Practice Center under Contract No. 290-02-0022.) AHRQ Publication No. 05-EO24-2. Rockville, MD Agency for Healthcare Research and Quality; July (2005).
85. Weggemans RM, Trautwein EA: Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: A meta-analysis. Eur. J. Clin. Nutr. 57, 940-946 (2003).
86. Zhan S, Ho SC: Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am. J. Clin. Nutr. 81, 397-408 (2005).
87. Zhuo XG, Melby MK, Watanabe S: Soy Isonavone Intake Lowers Serum LDL Cholesterol: A Meta-Analysis of 8 Randomized Controlled Trials in Humans. J. Nutr. 134, 2395-2400 (2004).
88. Gianazza E, Eberini I, Arnoldi A, Wait R, Sirtori CR: A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. J. Nutr. 133, 9-14 (2003).
89. Duranti M, Lovati MR, Dani V et al.: The α subunit from soybean 7S globulin lowers plasma lipids and upregulates liver β-VLDL receptors in rats fed a hypercholesterolemic diet. J. Nutr. 134, 1334-1339 (2004).
90. Lovati MR, Manzoni C, Gianazza E et al.: Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J. Nutr. 130, 2543-2549 (2000).
91. Gardner CD, Messina M, Kiazand A, Morris JC, Varady A, Franke A: Effect of two types of soy milk and dairy milk on plasma lipids in hypercholesterolemic adults: A randomized trial. Presented at: Sixth International Symposium on the Role of Soy in Preventing and Treating Chronic Disease. Chicago, IL, USA, 30 October-2 November 2005.
92. Sirtori CR, Gianazza E, Manzoni C, Lovati MR, Murphy PA: Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. Am. J. Clin. Nutr. 65, 166-167 (1997).
93. Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL: A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med. 159, 2070-2076 (1999).
94. Yeung J, Yu TF: Effects of isoflavones (soy phyto-estrogens) on serum lipids: A meta-analysis of randomized controlled trials. Nutr. J. 2, 15 (2003).
95. Fang N, Yu S, Badger TM: Comprehensive phytochemical profile of soy protein isolate. J. Agric. Food Chem. 52, 4012-4020 (2004).
96. Anderson RL, Wolf WJ: Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. J. Nutr. 125, S581-S588 (1995).
97. Lichtenstein AH, Jalbert SM, Adlercreutz H et al.: Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler. Thromb. Vasc. Biol. 22, 1852-1858 (2002).
98. Nestel P, Cehun M, Chronopoulos A, DaSilva L, Teede H, McGrath B: A biochanin-enriched isoflavone from red clover lowers LDL cholesterol in men. Eur. J. Clin. Nutr. 58, 403-408 (2004).
99. Petri Nahas E, Nahas Neto J, De Luca L, Traiman P, Pontes A, Dalben I: Benefits of soy germ isoflavones in postmenopausal women with contraindication for conventional hormone replacement therapy. Maturitas 48, 372-380 (2004).
100. Dewell A, Hollenbeck CB, Bruce B: The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J. Clin. Endocrinol. Metab. 87, 118-121 (2002).
101. Hale G, Paul-Labrador M, Dwyer JH, Merz CN: Isoflavone supplementation and endothelial function in menopausal women. Clin. Endocrinol. (Oxf.) 56, 693-701 (2002).
102. Honore EK, Williams JK, Anthony MS, Clarkson TB: Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil. Steril. 67, 148-154 (1997).
103. -/-) mice. Asia. Pac. J. Clin. Nutr. 13, S102 (2004).
104. Adams MR, Golden DL, Franke AA, Potter SM, Smith HS, Anthony MS: Dietary soy β-conglycinin (7S globulin) inhibits atherosclerosis in mice. J. Nutr. 134, 511-516 (2004).
105. Ni W, Tsuda Y, Sakono M, Imaizumi K: Dietary soy protein isolate, compared with casein, reduces atherosclerotic lesion area in apolipoprotein E-deficient mice. J. Nutr. 128, 1884-1889 (1998).
106. Zhang X, Shu XO, Gao YT et al.: Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J. Nutr. 133, 2874-2878 (2003).
107. Sasazuki S: Case-control study of nonfatal myocardial infarction in relation to selected foods in Japanese men and women. Jpn Circ. J. 65, 200-206 (2001).
108. Nagata C: Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int. J. Epidemiol. 29, 832-836 (2000).
109. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III] final report. Circulation 106, 3143-3421 (2002).
110. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260, 1917-1921 (1988).
111. Bjornheden T, Babyi A, Bondjers G, Wiklund O: Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123, 43-56 (1996).
112. Merz-Demlow BE, Duncan AM, Wangen KE et al.: Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am. J. Clin. Nutr. 71, 1462-1469 (2000).
113. Wangen KE, Duncan AM, Xu X, Kurzer MS: Soy isoflavones improve plasma lipids in normocholesterolemic and mildly hypercholesterolemic postmenopausal women. Am. J. Clin. Nutr. 73, 225-231 (2001).
114. Lamarche B, Lemieux I, Despres JP: The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 25, 199-211 (1999).
115. Stamler R: Implications of the INTERSALT study. Hypertension 17, I16-I20 (1991).
116. Rivas M, Garay RP, Escanero JF, Cia P Jr, Cia P, Alda JO: Soy milk lowers blood pressure in men and women with mild to moderate essential hypertension. J. Nutr. 132, 1900-1902 (2002).
117. Welty FK, Guida KA: Soy nuts lower systolic and diastolic blood pressure in hypertensive and normotensive menopausal women. American Heart Association Meeting (Abstract 3018) (2002).
118. Yang G, Shu XO, Jin F et al.: Longitudinal study of soy food intake and blood pressure among middle-aged and elderly Chinese women. Am. J. Clin. Nutr. 81, 1012-1017 (2005).
119. He J, Gu D, Wu X, Chen J, Duan X, Whelton PK: Effect of soybean protein on blood pressure: A randomized, controlled trial. Ann. Intern. Med. 143, 1-9 (2005).
120. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52, 223-261 (1983).
121. Chen K, Thomas SR, Keaney JF Jr: Beyond LDL oxidation: ROS in vascular signal transduction. Free Radic. Biol. Med. 35, 117-132 (2003).
122. Heinecke JW: Is the emperor wearing clothes? Clinical trials of vitamin E and the LDL oxidation hypothesis. Arterioscler. Thromb. Vasc. Biol. 21, 1261-1264 (2001).
123. Graf E, Eaton JW: Antioxidant functions of phytic acid. Free Radic. Biol. Med. 8, 61-69 (1990).
124. Pratt DE: Water soluble antioxidant activity of soybeans. J. Food Sci. 37, 322-323 (1972).
125. Pratt DE, Birac PM: Source of antioxidant activity of soybeans and soy products. J. Food Sci. 44, 1720-1722 (1979).
126. Romijn A, Cuppett SL, Zeece MG, Parkhurst AM, Lee ML: Impact of soy protein isolates and specific fractions on rancidity development in a cooked, refrigerated beef system. J. Food Sci. 56, 188-190 (1991).
127. Ruiz-Larrea MB, Mohan AR, Paganga G, Miller NJ, Bolwell GP, Rice-Evans CA: Antioxidant activity of phytoestrogenic isoflavones. Free Radic. Res. 26, 63-70 (1997).
128. Cao G, Sofic E, Prior RL: Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships. Free Radic. Biol. Med. 22, 749-760 (1997).
129. Chen H-M, Muramoto K, Yamauchi F: Structural analysis of antioxidative peptides from soybeans B-conglycinin. J. Agric. Food Chem. 43, 574-578 (1995).
130. Chen H-M, Muramoto K, Yamauchi F, Nokihara K: Antioxidant activity of designed peptides based on the antioxidative peptide isolated from digests of a soybean protein. J. Agr. Food Chem. 44, 2619-2633 (1996).
131. Chen HM, Muramoto K, Yamauchi F, Fujimoto K, Nokihara K: Antioxidative properties of histidine-containing peptides Designed from peptide fragments found in the digests of a soybean protein. J. Agric. Food Chem. 46, 49-53 (1998).
132. Aoki H, Otaka Y, Igarashi K, Takenaka A: Soy protein reduces paraquat-induced oxidative stress in rats. J. Nutr. 132, 2258-2262 (2002).
133. Takenaka A, Annaka H, Kimura Y, Aoki H, Igarashi K: Reduction of paraquat-induced oxidative stress in rats by dietary soy peptide. Biosci. Biotechnol. Biochem. 67, 278-283 (2003).
134. Manzoni C, Duranti M, Eberini I et al.: Subcellular localization of soybean 7s globulin in hepg2 cells and ldl receptor up-regulation by its alpha' constituent subunit. J. Nutr. 133, 2149-2155 (2003).
135. Kanazawa T, Osanai T, Zhang XS et al.: Protective effects of soy protein on the peroxidizability of lipoproteins in cerebrovascular diseases. J. Nutr. 125, S639-S646 (1995).
136. Tikkanen MJ, Adlercreutz H: Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention? Biochem. Pharmacol. 60, 1-5 (2000).
137. Ashton E, Ball M: Effects of soy as tofu vs meat on lipoprotein concentrations. Eur. J. Clin. Nutr. 54, 14-19 (2000).
138. Jenkins DJ, Kendall CWC, Jackson C-J et al.: Effects of high and low-isoflavone soyfoods on blood lipid, oxidized LDL, homocysteine, and blood pressure in hyperlipidemic men and women. Am. J. Clin. Nutr. 76, 365-372 (2002).
139. Jenkins DJ, Kendall CW, Vidgen E et al.: Effect of soy-based breakfast cereal on blood lipids and oxidized low- density lipoprotein. Metabolism 49, 1496-500 (2000).
140. Jenkins DJ, Kendall CW, Garsetti M et al.: Effect of soy protein foods on low-density lipoprotein oxidation and ex vivo sex hormone receptor activity - a controlled crossover trial. Metabolism 49, 537-543 (2000).
141. Scheiber MD, Liu JH, Subbiah MT, Rebar RW, Setchell KD: Dietary inclusion of whole soy foods results in significant reductions in clinical risk factors for osteoporosis and cardiovascular disease in normal postmenopausal women. Menopause 8, 384-392 (2001).
142. Stephenson TJ, Setchell KD, Kendall CW, Jenkins DJ, Anderson JW, Fanti P: Effect of soy protein-rich diet on renal function in young adults with insulin-dependent diabetes mellitus. Clin. Nephrol. 64, 1-11 (2005).
143. Nestel PJ, Yamashita T, Sasahara T et al.: Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler. Thromb. Vasc. Biol. 17, 3392-3398 (1997).
144. Samman S, Lyons Wall PM, Chan GS, Smith SJ, Petocz P: The effect of supplementation with isoflavones on plasma lipids and oxidisabillty of low density lipoprotein in premenopausal women. Atherosclerosis 147, 277-283 (1999).
145. Gardner-Thorpe D, O'Hagen C, Young I, Lewis SJ: Dietary supplements of soya flour lower serum testosterone concentrations and improve markers of oxidative stress in men. Eur. J. Clin. Nutr. 57, 100-106 (2003).
146. Hazen SL, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density liproprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99, 2075-2081 (1997).
147. Davis JN, Kucuk O, Djuric, Z, Sarkar FH. Soy isoflavone supplementation in healthy men prevents NF-κB activation by TNF-α in blood lymphocytes. Free Radic. Biol. Med. 30, 1293-1302 (2001).
148. Djuric Z, Chen G, Doerge DR, Heilbrun LK, Kucuk O: Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett. 172, 1-6 (2001).
149. Ryan-Borchers TA, Park JS, Chew BP, McGuire MK, Fournier LR, Beerman KA: Soy isoflavones modulate immune function in healthy postmenopausal women. Am. J. Clin. Nutr. 83, 1118-1125 (2006).
150. Cesari M, Rossi GP, Sticchi D, P essina AC: Is homocysteine important as risk factor for coronary heart disease? Nutr. Metab. Cardiovasc. Dis. 15, 140-147 (2005).
151. Nagata C, Shimizu H, Takami R, Hayashi M, Takeda N, Yasuda K: Soy product intake is inversely associated with serum homocysteine level in premenopausal Japanese women. J. Nutr. 133, 797-800 (2003).
152. Hagemeister H, Scholz-Ahrens KE, Schulte-Coerne H, Barth CA: Plasma amino acids and cholesterol following consumption of dietary casein or soy protein in minipigs. J. Nutr. 120, 1305-1311 (1990).
153. Le Leu RK, McIntosh GH, Young GP: Ability of endogenous folate from soy protein isolate to maintain plasma homocysteine and hepatic DNA methylation during methyl group depletion in rats. J. Nutr. Sci. Vitaminol. (Tokyo) 4, 457-464 (1998).
154. Gudbrandsen CA, Wergedahl H, Liaset B, Espe M, Berge RK: Dietary proteins with high isoflavone content or low methionine-glycine and lysine-arginine ratios are hypocholesterolaemic and lower the plasma homocysteine level in male Zucker fa/fa rats. Br. J. Nutr. 94, 321-330 (2005).
155. Jenkins DJ, Kendall CW, Connelly PW et al.: Effects of high- and low-isoflavone (phytoestrogen) soy foods on inflammatory biomarkers and proinflammatory cytokines in middle-aged men and women. Metabolism 51, 919-924 (2002).
156. Hermansen K, Sondergaard M, Hole L, Carstensen M, Brock B: Beneficial effects of a soy-based dietary supplement on lipid levels and cardiovascular risk markers in type 2 diabetic subjects. Diabetes Care 24, 228-233 (2001).
157. Puska P, Korpelainen V, Hoie LH, Skovlund E, Lahti T, Smerud KT. Soy in hypercholesterolaemia: A double-blind, placebo-controlled trial. Eur. J. Clin. Nutr. 56, 352-357 (2002).
158. Puska P, Korpelainen V, Hole LH, Skovlund E, Smerud KT: Isolated soya protein with standardised levels of isonavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation. Br. J. Nutr.. 91, 393-401 (2004).
159. Tonstad S, Smerud K, Hoie L: A comparison of the effects of 2 doses of soy protein or casein on serum lipids, serum lipoproteins, and plasma total homocysteine in hypercholesterolemic subjects. Am. J. Clin. Nutr.. 76, 78-84 (2002).
160. Lukaczer D, Deann JL, Lerman RH et al.: Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 22, 104-113 (2006).
161. Roughead ZK, Hunt JR, Johnson LK, Badger TM, Lykken GI: Controlled substitution of soy protein for meat protein: Effects on calcium retention, bone, and cardiovascular health indices in postmenopausal women. J. Clin. Endocrinol. Metab. 90, 181-189 (2005).
162. Hermansen K, Hansen B, Jacobsen R et al.: Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects. Eur. J. Clin. Nutr. 59, 843-850 (2005).
163. Reimann M, Dierkes J, Carlsohn A et al.: Consumption of soy isoflavones does not affect plasma total homocysteine or asymmetric dimethylarginine concentrations in healthy postmenopausal women. J. Nutr: 136, 100-105 (2006).
164. Bonaa KH, Njolstad I, Ueland PM et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354, 1578-1588 (2006).
165. Loon E, Yusuf S, Arnold MJ et al.: Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 354, 1567-1577 (2006).
166. Toole JF, Malinow MR, Chambless LE et al.: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. Jama 291, 565-575 (2004).
167. Mora S, Ridker PM: Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am. J. Cardiol. 97, A33-A41 (2006).
168. Ridker PM: High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. Am. Heart J. 148, S19-S26 (2004).
169. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE: Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100, 713-716 (1999).
170. Pradhan AD, Manson JE, Rossouw JE et al.: Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. Jama 288, 980-987 (2002).
171. Nikander E, Metsa-Heikkila M, Tutinen A, Ylikorkala O: Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women. J. Clin. Endocrinol. Metab. 88, 5180-5185 (2003).
172. Hall WL, Vafeiadou K, Hallund J et ai.: Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: Interactions with genotype and equol production. Am. J. Clin. Nutr. 82, 1260-1268 (2005).
173. Fanti P, Asmis R, Stephenson TJ, Sawaya BP Franke AA: Positive effect of dietary soy in ESRD patients with systemic inflammation-correlation between blood levels of the soy isoflavones and the acute-phase reactants. Nephrol. Dial. Transplant. 21, 2239-2246 (2006).
174. McVeigh BL, Dillingham BL, Lampe JW, Duncan AM: Effect of soy protein varying in Isoflavone content on serum lipids in healthy young men. Am. J. Clin. Nutr. 83, 244-251 (2006).
175. Colacurci N, Chiantera A, Fornaro F et al.: Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 12, 299-307 (2005).
176. Hilpert KF, Kris-Etherton PM, West SG: Lipid response to a low-fat diet with or without soy is modified by C-reactive protein status in moderately hypercholesterolemic adults. J. Nutr. 135, 1075-1079 (2005).
177. Li Z, Hong K, Saltsman P et al.: Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: Relative effects on weight loss, metabolic parameters, and C-reactive protein. Eur. J. Clin. Nutr. 59, 411-418 (2005).
178. Herrington DM, Brown WV, Mosca L et al.: Relationship between arterial stiffness and subclinical aortic atherosclerosis. Circulation 110, 432-437 (2004).
179. Meyer BJ, Larkin TA, Owen AJ, Astheimer LB, Tapsell LC, Howe PR: Limited lipid-lowering effects of regular consumption of whole soybean foods. Ann. Nutr. Metab. 48, 67-78 (2004).
180. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP: Dietary soy has both beneficial and potentially adverse cardiovascular effects: A placebo-controlled study in men and postmenopausal women. J. Clin. Endocrinol. Metab. 86, 3053-6300 (2001).
181. Hallund J, Bugel S, Tholstrup T et al.: Soya isoflavone-enriched cereal bars affect markers of endothelial function in postmenopausal women. Br. J. Nutr. 95, 1120-1126 (2006).
182. Nestel P, Fujii A, Zhang L: An isoflavone metabolite reduces arterial stiffness and blood pressure in overweight men and postmenopausal women. Atherosclerosis (2006).
183. Yamashita T, Sasahara T, Pomeroy SE, Collier G, Nestel PJ: Arterial compliance, blood pressure, plasma leptin, and plasma lipids in women are improved with weight reduction equally with a meat-based diet and a plant-based diet. Metabolism 47, 1308-1314 (1998).
184. Tsunoda N, Pomeroy S, Nestel P: Absorption in humans of isoflavones from soy and red clover is similar. J. Nutr. 132, 2199-2201 (2002).
185. Nestel PJ, Pomeroy S, Kay S et al.: Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J. Clin. Endocrinol. Metab. 84, 895-898 (1999).
186. Teede HJ, McGrath BP, DeSilva L, Cehun M, Fassoulakis A, Nestel PJ: Isoflavones reduce arterial stiffness: A placebo-controlled study in men and postmenopausal women. Arterioscler. Thromb. Vasc. biol. 23, 1066-1071 (2003).
187. Bonetti PO, Lerman AO, Lerman A: Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. biol. 23, 168-175 (2003).
188. Walker HA, Dean TS, Sanders TA, Jackson G, Ritter JM, Chowienczyk PJ: The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vascutature with similar potency to 17b-Estradiol. Circulation 103, 258-262 (2001).
189. Squadrito F, Altavilla D, Crisafulli A et al.: Effect of genistein on endothelial function in postmenopausal women: A randomized, double-blind, controlled study. Am. J. Med.. 114, 470-476 (2003).
190. Squadrito F, Altavilla D, Morabito N et al.: The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women. Atherosclerosis 163, 339-347 (2002).
191. Yildirir A, Tokgozoglu SL, Oduncu T et al.: Soy protein diet significantly improves endothelial function and lipid parameters. Clin. Cardiol. 24, 711-716 (2001).
192. Blum A, Lang N, Vigder F et al.: Effects of soy protein on endothelium-dependent vasodilatation and lipid profile in postmenopausal women with mild hypercholesterolemia. Clin. Invest. Med. 26, 20-26 (2003).
193. Kreijkamp-Kaspers S, Kok L, Bots ML, Grobbee DE, Lampe JW, van der Schouw YT: Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. Am. J. Clin. Nutr. 81, 189-195 (2005).
194. Simons LA, von Konigsmark M, Simons J, Celermajer DS: Phytoestrogens do not influence lipoprotein, levels or endothelial function in healthy, postmenopausal women. Am. J. Cardiol. 85, 1297-1301 (2000).
195. Lissin LW, Oka R, Lakshmi S, Cooke JP: Isoflavones improve vascular reactivity in post-menopausal women with hypercholesterolemia. Vasc. Med. 9, 26-30 (2004).
196. Pereira JR, Faludi AA, Aldrighi JM et al.: Effects of soy germ isoflavones and hormone therapy on nitric oxide derivatives, low-density lipoprotein oxidation, and vascular reactivity in hypercholesterolemic postmenopausal women. Menopause (2006).
197. Teede HJ, Dalais FS, Kotsopoulos D et al.: Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J. Clin. Endocrinol. Metab. 90, 1936-1941 (2005).
198. Cupisti A, Ghiadoni L, D'Alessandro C et al.: Soy protein diet improves endothelial dysfunction in renal transplant patients. Nephrol. Dial. Thansplant. (2006).
199. Evans M, Njike VY, Hoxley M, Pearson M, Katz DL: Effect of soy isollavone protein and soy lecithin on endothelial function in healthy postmenopausal women. Menopause (2006).
200. Law MR, Wald NJ, Thompson SG: By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br. Med. J. 308, 367-372 (1994).
201. Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A: Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: Data from the BUPA study. Br. Med. J. 308, 363-366 (1994).
202. Jenkins DJ, Kendall CW, Marchie A et al.: Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. Jama 290, 502-510 (2003).
203. Jones PH. Davidson MH, Stein EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin. and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 92, 152-160 (2003).
204. Moreyra, AE, Wilson AC, Koraym A: Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch. Intern. Med. 165, 1161-1166 (2005).
205. Smit E, Nieto FJ, Crespo CJ, Mitchell P: Estimates of animal and plant protein intake in US adults: Results from the Third National Health and Nutrition Examination Survey, 1988-1991. J. Am. Diet Assoc. 99, 813-820 (1999).
206. Willamson-Hughes PS, Flickinger BD, Messina MJ, Empie MW: Isoflavone supplements containing predominantly genistein reduce hot flash symptoms: A critical review of published studies. Menopause 13, 831-839 (2006).
207. Urban D, Irwin W, Kirk M et al.: The effect of isolated soy protein on plasma biomarkers in elderly men with elevated serum prostate specific antigen. J. Urol. 165, 294-300 (2001).
208. Garrido A, De la Maza MP, Hirsch S, Valladares L: Soy isoflavones affect platelet thromboxane A2 receptor density but not plasma lipids in menopausal women. Maturitas 54, 270-276 (2006).
209. Ishiwata N, Ueno T, Uschiyama S, Watanabe H: A randomized placebo-controlled trial of oral supplement for treatment of menopausal symptoms among Japanese women. Presented at: 4th International Soy and Health Conference. Düsseldorf, Germany, 12-13 October 2006.